May 17, 2012
/PRNewswire/ -- ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that customer demand and unit sales of its recently launched
line of dietary supplements have exceeded the Company's initial forecast and expectations during the first quarter ended
March 31, 2012
The nationwide launch of BluScience™ in retail outlets began in earnest in early 2012 whereby BluScience™ became available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S.
In the first quarter of 2012, the initial launch achieved sales of more than 125,000 units of BluScience™, more than 50 percent higher than the Company's initial forecast. Sales deductions for promotions and discounts related to the sale of BluScience™ product totaled
in the first quarter, resulting in net sales of BluScience™ products of
. Higher than expected consumer demand for the BluScience™ line resulted in higher than expected promotional expenses.
As planned, promotional activities, discounted pricing and media programs were used to generate interest, and played a key role in the launch and initial consumer awareness of the product line.
, Co-Founder and CSO of ChromaDex
made a strategic decision to significantly invest in our patented and proprietary
by creating and launching the BluScience™ product line as well as financing the first human clinical study of pTeroPure
. The results will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product."
the successful completion of enrollment in the first human clinical study of pTeroPure
. The randomized, double-blind placebo-controlled study evaluated pTeroPure
effects on blood pressure, total triglycerides, cholesterol, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure
in these patients and other ends points, such as weight loss.
The BluScience™ line is currently comprised of:
- EternalBlu - supports cellular health and has anti-aging properties
- HeartBlu - helps maintain healthy cholesterol levels and supports cardiovascular health
- MemoryBlu - supports concentration, memory and cognitive function
- TrimBlu - helps control appetite and supports healthy metabolism
- Blu2Go - provides a sustained energy boost and supports focus & mental clarity
The novel ingredient in BlūScience™ is ChromaDex
's proprietary, patented pterostilbene, branded as
, which was named the
2010 North American Most Promising Ingredient of the Year
by the independent research company, Frost & Sullivan.
is a proprietary, nature-identical formulation of the compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (phytochemicals with antioxidant activities that help fight free radicals), allowing more time for its antioxidant activities to act. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience™ capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure
pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience™ line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in
is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex
is also investigating pTeroPure
for the skincare and pharmaceutical markets, among others. pTeroPure
is currently being studied in a human clinical trial at the University of Mississippi. For more information about pTeroPure
or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.